日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Genetic mechanisms of resistance to targeted KRAS inhibition.

针对KRAS靶向抑制的耐药遗传机制

Diaz Bianca J, Kops Max, Bernardo Sara, Schmidt Henri, Grankowsky Elizabeth, Vega Adrian, Zhang Chen, Bott Matthew, Skamagki Maria, Tomlinson Aidan, Vita Nicole A, Katti Alyna, Labrecque Mark P, Aronchik Ida, Singh Mallika, Dow Lukas E

Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer

靶向去势抵抗性前列腺癌分子亚型中的成纤维细胞生长因子通路

Labrecque, Mark P; Brown, Lisha G; Coleman, Ilsa M; Nguyen, Holly M; Dalrymple, Susan; Brennen, W Nathaniel; Isaacs, John T; Li, Dapei; Lakely, Bryce; DeLucia, Diana C; Lee, John K; Schweizer, Michael T; Lin, Daniel W; Corey, Eva; Nelson, Peter S; Morrissey, Colm

RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer

RNA剪接因子SRRM3和SRRM4可区分去势抵抗性神经内分泌前列腺癌的分子表型

Labrecque, Mark P; Brown, Lisha G; Coleman, Ilsa M; Lakely, Bryce; Brady, Nicholas J; Lee, John K; Nguyen, Holly M; Li, Dapei; Hanratty, Brian; Haffner, Michael C; Rickman, David S; True, Lawrence D; Lin, Daniel W; Lam, Hung-Ming; Alumkal, Joshi J; Corey, Eva; Nelson, Peter S; Morrissey, Colm

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.

BET溴结构域抑制剂阻断了AR抑制、E2F1激活的治疗后出现的神经内分泌前列腺癌谱系可塑性程序

Kim Dae-Hwan, Sun Duanchen, Storck William K, Welker Leng Katherine, Jenkins Chelsea, Coleman Daniel J, Sampson David, Guan Xiangnan, Kumaraswamy Anbarasu, Rodansky Eva S, Urrutia Joshua A, Schwartzman Jacob A, Zhang Chao, Beltran Himisha, Labrecque Mark P, Morrissey Colm, Lucas Jared M, Coleman Ilsa M, Nelson Peter S, Corey Eva, Handelman Samuel K, Sexton Jonathan Z, Aggarwal Rahul, Abida Wassim, Feng Felix Y, Small Eric J, Spratt Daniel E, Bankhead Armand 3rd, Rao Arvind, Gesner Emily M, Attwell Sarah, Lakhotia Sanjay, Campeau Eric, Yates Joel A, Xia Zheng, Alumkal Joshi J

The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches

缺乏雄激素受体(AR)活性的前列腺癌具有异质性,因此需要采取不同的治疗方法。

Labrecque, Mark P; Alumkal, Joshi J; Coleman, Ilsa M; Nelson, Peter S; Morrissey, Colm

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts

恩扎卢胺耐药性前列腺癌对超生理睾酮的持久反应与患者来源异种移植瘤中多方面的生长抑制和DNA损伤反应转录组程序受损有关

Lam, Hung-Ming; Nguyen, Holly M; Labrecque, Mark P; Brown, Lisha G; Coleman, Ilsa M; Gulati, Roman; Lakely, Bryce; Sondheim, Daniel; Chatterjee, Payel; Marck, Brett T; Matsumoto, Alvin M; Mostaghel, Elahe A; Schweizer, Michael T; Nelson, Peter S; Corey, Eva

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer

分子谱分析可对难治性转移性去势抵抗性前列腺癌的不同表型进行分层

Labrecque, Mark P; Coleman, Ilsa M; Brown, Lisha G; True, Lawrence D; Kollath, Lori; Lakely, Bryce; Nguyen, Holly M; Yang, Yu C; da Costa, Rui M Gil; Kaipainen, Arja; Coleman, Roger; Higano, Celestia S; Yu, Evan Y; Cheng, Heather H; Mostaghel, Elahe A; Montgomery, Bruce; Schweizer, Michael T; Hsieh, Andrew C; Lin, Daniel W; Corey, Eva; Nelson, Peter S; Morrissey, Colm

Estrogen receptor expression is required for low-dose resveratrol-mediated repression of aryl hydrocarbon receptor activity

雌激素受体表达是低剂量白藜芦醇介导的芳烃受体活性抑制所必需的。

Perdew, Gary H; Hollingshead, Brett D; Dinatale, Brett C; Morales, J Luis; Labrecque, Mark P; Takhar, Mandeep K; Tam, Kevin J; Beischlag, Timothy V